{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"48","upperLimit":"78","value":"64"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"44"}],"units":"Participants"}],"description":"24-month progression-free survival is defined as the proportion of patients who were alive and progression-free at 24 months post registration. The primary study population for this endpoint is patients who were confirmed post-induction clinical complete response (CR) at their primary sites and subsequently received 5400 cGy radiation therapy to their primary sites.","dispersionType":"95% Confidence Interval","groups":[{"description":"The primary study population for this endpoint is patients who were confirmed post-induction clinical complete response (CR) at their primary sites and subsequently received 5400 cGy radiation therapy to their primary sites.","id":"OG000","title":"Primary Study Population"}],"paramType":"NUMBER","populationDescription":"patients who were confirmed post-induction clinical complete response (CR) at their primary sites and subsequently received 5400 cGy radiation therapy to their primary sites","reportingStatus":"POSTED","timeFrame":"assessed within 14 days after delivery of the third cycle of induction therapy, and 8 weeks and 6 months after completion of concurrent therapy, then every 6 months until progression or until 3 years from study entry","title":"24-month Progression-free Survival","type":"PRIMARY","unitOfMeasure":"percentage of participants"}